In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

A global analysis of associations between fine particle air pollution and blood pressure, lipids, and glucose in patients with coronary heart disease of the Survey of Risk Factors (SURF) study

Session Poster Session 2

Speaker Min Zhao

Congress : EuroPrevent 2019

  • Topic : preventive cardiology
  • Sub-topic : Environmental and Occupational Aspects of Heart Disease
  • Session type : Poster Session
  • FP Number : P439

Authors : MZ Zhao (Utrecht,NL), GH Hoek (Utrecht,NL), MS Strak (Utrecht,NL), DEG Grobbee (Utrecht,NL), IG Graham (Dublin,IE), KKG Klipstein-Grobusch (Utrecht,NL), IV Vaartjes (Utrecht,NL)

15 views

Authors:
MZ Zhao1 , GH Hoek2 , MS Strak2 , DEG Grobbee1 , IG Graham3 , KKG Klipstein-Grobusch1 , IV Vaartjes1 , 1University Medical Center Utrecht - Utrecht - Netherlands (The) , 2Institute for Risk Assessment Sciences, Environmental epidemiology - Utrecht - Netherlands (The) , 3Trinity College Dublin - Dublin - Ireland ,

Citation:

Background: Studying the associations between particulate air pollution and cardiovascular risk factors on a global scale is challenging and rarely done. We aimed to determine the associations of long-term exposure to particles smaller than 2.5µm (PM2.5) with systolic and diastolic blood pressure (SBP/DBP), lipids (total, low-density, and high-density cholesterol), and glucose using existing data from 10 countries in Europe, Asia, and the Middle-East.
Methods: Cardiovascular risk factor data were obtained from the SUrvey of Risk Factors (SURF) for coronary heart disease (CHD) patients. Annual average PM2.5 concentrations were estimated using recent global WHO PM2.5 maps combining satellite and surface monitoring data for the location of the 71 participating centers. Associations of PM2.5 with risk factors were assessed by mixed-effect generalized estimation equation models adjusted by sex, age, exercise, and smoking. We assessed whether additional adjustment for country affected associations.
Results: 8392 patients (30% women) were included. Globally, an increase of 10 µg/m3 in PM2.5 was significantly associated with decreased BP and increased glucose. No associations were found with lipids. After controlling for country, an increase of 10 µg/m3 in PM2.5 was associated with decreased BP and increased LDL (SBP: -0.45mmHg, 95% CI: -0.85, -0.06;DBP: -0.47mmHg, 95% CI: -0.73, -0.20;LDL: 0.04mmol/L, 95%CI: 0.01, 0.08). The association with glucose attenuated (0.08mmol/L, 95% CI: -0.23, 0.16).
Conclusion: Global associations of PM2.5 and cardiovascular risk factors can be determined linking risk factor and geospatial air pollution data but the sensitivity of effect estimates to adjustment for country stress the need for multiple centers per country. After country adjustment, PM2.5 was associated with small increases in LDL and small decreases in BP.

SURF Global

SURF Europe

PM2.5 (μg/m3)

Mean

38.1±34.5

15.8±5.7

SBP (mmHg)

Changes (95%CI)

-0.45(-0.85, -0.05)

-1.3 (-6.70, 4.11)

DBP (mmHg)

Changes (95%CI)

-0.47 (-0.73, -0.20)

-1.13 (-3.52, 1.30)

TC (mmol/L)

Changes (95%CI)

0.02 (-0.03, 0.07)

-0.11 (-0.93, 0.71)

LDL (mmol/L)

Changes (95%CI)

0.04 (0.01, 0.08)

-0.02 (-0.53, 0.50)

HDL (mmol/L)

Changes (95%CI)

0.01 (-0.01, 0.03)

-0.04 (-0.14, 0.22)

Glucose (mmol/L)

Changes (95%CI)

-0.08 (-0.24, 0.07)

0.0001 (-0.43, 0.43)

SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol. Changes in cardiovascular risk factors were assessed by 10 µg/m3 increased in PM2.5. Adjustments include gender, age, exercise, smoking habit, and country.


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are